Introduction {#s1}
============

Clathrin-coated vesicles (CCVs) are key players in eukaryotic intracellular membrane traffic ([@bib13]). Their characteristic lattice-like coat is self-assembled from cytoplasmic clathrin proteins, captures membrane-embedded protein cargo and deforms the membrane into a vesicle. This process enables CCVs to mediate protein transport to and from the plasma membrane and between organelles. The triskelion-shaped clathrin molecule is formed from three identical clathrin heavy chain (CHC) subunits. Humans have two genes (*CLTC* and *CLTCL1*) that respectively encode CHC17 and CHC22 clathrins ([@bib90]). CHC17 clathrin, which has three bound clathrin light chain (CLC) subunits, is expressed uniformly in all tissues and forms CCVs that control receptor-mediated endocytosis, as well as lysosome biogenesis and maturation of regulated secretory granules. These pathways are conventionally associated with clathrin function and are mediated by clathrin in all eukaryotic cells ([@bib13]). In humans CHC22 clathrin is most highly expressed in muscle and adipose tissue and forms separate CCVs that are not involved in endocytosis ([@bib21]). In these tissues, CHC22 CCVs regulate targeting of the glucose transporter 4 (GLUT4) to an intracellular compartment where it is sequestered until released to the cell surface in response to insulin ([@bib88]). This insulin-responsive GLUT4 pathway is the dominant mechanism in humans for clearing blood glucose into muscle and fat tissues after a meal ([@bib78]). In addition to its distinct tissue expression pattern and biological function, CHC22 does not bind the CLC subunits that associate with CHC17 clathrin, even though the CHC protein sequences are 85% identical ([@bib21]; [@bib53]). This remarkable biochemical and functional divergence evolved since the gene duplication event that gave rise to the two different clathrins during the emergence of chordates ([@bib90]). Notably, however, the *CLTCL1* gene encoding CHC22 evolved into a pseudogene in the *Mus* genus, although mice maintain an insulin-responsive GLUT4 pathway for clearing blood glucose. This observation suggests that, despite the importance of the *CLTCL1* gene product, backup pathways have evolved to compensate for loss of the CHC22 protein. To understand the evolution of the specialized function of CHC22, and the potential selective processes involved, we here explore the phylogenetic history of the *CLTCL1* gene in vertebrates and its population genetics in humans, non-human primates and bears.

Ecological shifts create selective forces that filter variation in cellular genes. These include changes in nutritional conditions ([@bib6]), as well as encounters with pathogens ([@bib33]); both documented as selective forces that affect membrane traffic genes ([@bib27]; [@bib54]). Recent studies of the evolution of genes involved in membrane traffic have focused on an overview of all eukaryotes with the goals of establishing the origins of membrane-traffic regulating proteins in the last common eukaryotic ancestor and defining the species distribution of various families of traffic-regulating proteins ([@bib75]; [@bib19]). These studies have identified common features of proteins that regulate membrane traffic ([@bib75]) and revealed that extensive gene duplication has allowed lineage-specific diversification of coat proteins and other membrane traffic regulators, such as the Rab GTPases ([@bib24]; [@bib36]). Our earlier study of available annotated genomes in 2005 suggested that the gene duplication giving rise to the two CHC-encoding genes occurred as a result of one of the whole genome duplications contributing to vertebrate evolution ([@bib90]). Here we focus on the more recent evolutionary history of these genes, as well as analyze the increased number of fully annotated vertebrate genomes. We establish that the loss of *CLTCL1* in the *Mus* genus is not unique in vertebrates, identifying at least one additional independent gene loss event in the clade of Cetartiodactyla affecting pigs, cows, sheep, porpoise, and possibly additional related species. Nonetheless, there is strong evidence for CHC22 sequence conservation amongst those species that retain *CLTCL1* ([@bib90]). This evolutionarily recent gene loss in some lineages and retention of the functional form in others suggested that *CLTCL1* may still be under purifying selection, so we examined *CLTCL1* variation between individuals within vertebrate populations. Comparing populations, we found *CLTCL1* to be considerably more polymorphic than *CLTC*, which encodes the clathrin found in all eukaryotes, with evidence for strong ancient purifying selection for CHC17 clathrin function and relaxed purifying selection on CHC22 function. Additionally, we identified two common allotypes of human CHC22, which have different functional properties. The derived allele arose in ancient humans and is more frequent in farming populations when compared to hunter-gatherers. We previously observed that CHC22 accumulates at sites of GLUT4 retention in the muscle of insulin-resistant patients with type two diabetes ([@bib88]) in addition to its active role in membrane traffic of GLUT4. Thus, CHC22 variation has potential to differentially affect membrane traffic pathways involved in insulin resistance, as well as alter normal glucose metabolism within human and other vertebrate populations. The analyses reported here lead us to propose that variation in the CHC22 clathrin coat may be a response to changing nutritional pressures both between and within vertebrate species.

Results {#s2}
=======

Phylogenetic analyses reveal selective loss or retention of a functional *CLTCL1* gene in vertebrates {#s2-1}
-----------------------------------------------------------------------------------------------------

Identification of CHC-encoding genes in 62 vertebrate and non-vertebrate species (([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) indicates a dynamic history of gene duplications and losses ([Figure 1](#fig1){ref-type="fig"}). The *CLTCL1* gene was detected only in jawed vertebrates (bony vertebrates and cartilaginous fish), while the two jawless vertebrate genomes available -- lamprey (*Petromyzon marinus*) and hagfish (*Eptatretus burgeri*) -- have only one CHC-encoding gene. This distribution refines the timing of the CHC-encoding gene duplication to the period after the Agnatha split off the vertebrate lineage, estimated at 493.8MYA (95% HPD: 459.3, 533.8), and before the evolution of jawed vertebrates 450.8MYA (95% HPD: 432.1, 468.1) ([@bib42]; [@bib25]). Of the ten species of bony fish that split off the spotted gar (*Lepisosteus oculatus*) lineage ([@bib4]), whose genomes are generally tetraploid, all had two versions of *CLTC* and at least one *CLTCL1* gene, except for cave fish (*Astyanax mexicanus*) apparently lacking *CLTCL1*. Eight additional species of vertebrates with high genome coverage and reliable annotation had the *CLTC* gene but no identifiable *CLTCL1* gene. *CLTCL1* genes are present in the Caviomorpha and Sciuridae rodent suborders, and lost in the Muroidea suborder from the entire *Mus* genus ([@bib90]) and from rat (*Rattus norvegicus*). The Cetartiodactyla clade also appears to have lost *CLTCL1*, as *CLTCL1* is absent from the four representative genomes in our dataset (pig (*Sus scrofa*), sheep (*Ovis aries*), cow (*Bos taurus*), Yangtze finless porpoise (*Neophocaena asiaeorientalis*)). This suggests a loss event before the Cetartiodactyla lineage split, independent of the loss event preceding split of the Muroidea lineage. The absence of *CLTCL1* in rat clarifies why CHC22 could not be biochemically identified in rat and indicates that antibodies against CHC22 that react with rat cells must cross-react with other proteins ([@bib86]). *CLTCL1* was also not detected in the genomes of the little brown bat (*Myotis lucifugus*) and the duck-billed platypus (*Ornithorhynchus anatinus*). Assuming the genome annotations for the species analyzed are reliable, these data indicate that there have been at least five independent losses of *CLTCL1* that are clade- or species-specific. The intermittent loss of *CLTCL1* and the retention of *CLTC* raises the question of whether their patterns of evolution are typical for genes with related functions that duplicated in the same time frame as *CLTC/CLTCL1*.

![Phylogenetic analysis of *CLTC/CLTCL1* reveals independent loss of the gene encoding CHC22 clathrin from vertebrate lineages and complete conservation of the gene encoding CHC17 clathrin.\
Phylogenetic profiles *of CLTC/CLTCL1* are shown, with gene presence in the corresponding genome indicated by a filled black circle. All sequences used have less than 5% unspecified residues ('X's in the relevant database). Divergent gene sequences with low sequence similarity but that still fall within the *CLTC* clade are shown as empty circles (see Materials and methods for similarity threshold and sequence IDs). Based on the profile and species tree the most parsimonious phylogenetic tree for loss and duplication events is inferred and shown as red stars and blue squares, respectively.](elife-41517-fig1){#fig1}

*CLTC* and *CLTCL1* are located on paralogous regions of human chromosomes 17 and 22, respectively. For these two genes, the evolutionary rates (rate of non-synonymous substitutions to rate of synonymous substitutions; dN/dS) across vertebrates at each position were determined and plotted along the length of the protein sequences ([Figure 2A--B](#fig2){ref-type="fig"}). Several adjacent paralogs have been maintained in these chromosomal regions, some of which are involved in membrane traffic, including the gene pair of *MTMR4* and *MTMR3*, encoding myotubularin lipid phosphatases. Also, CLC subunits of CHC17 clathrin are encoded by paralogous genes on different chromosomes (*CLTA* and *CLTB*) that arose from a local gene duplication, mapped to the same time frame as the CHC-encoding duplication ([@bib90]). Comparison of the distribution of dN/dS ratios for the three pairs revealed stronger purifying selection on the *CLTC/CLTCL1* genes than on *MTMR4/MTMR3* and *CLTA/CLTB* ([Figure 2C--E](#fig2){ref-type="fig"}), suggesting the CHC-encoding clade is more evolutionarily constrained. This observation is consistent with our previous identification of conserved signature residues in *CLTCL1* using DIVERGE analysis ([@bib90]) and indicates conserved functions for both the *CLTC* and *CLTCL1* gene products. Furthermore, there is a striking difference in the distribution and average of evolutionary rates, as measured by dN/dS, between *CLTC* and *CLTCL1* (Kolmogorov-Smirnov test p-value\<2.2e-16), with *CLTC* being significantly more constrained by purifying selection than *CLTCL1*. In contrast, there is minimal difference in the distribution and average of evolutionary rates between the two paralog pairs *MTMR4/MTMR3* and *CLTA/CLTB* (Kolmogorov-Smirnov test yields *p*-values 0.003643 and 0.9959, respectively).

![Genes encoding clathrin heavy chains show evidence for purifying selection with *CLTCL1* (CHC22-encoding) being more variable than *CLTC* (CHC17-encoding) over evolutionary time.\
Evolutionary rates expressed as dN/dS ratios are shown for each position in *CLTC* (**A**) and *CLTCL1* (**B**). Rates are averages over an entire phylogenetic tree and therefore not specific to the human proteins. However, to assist interpretation, only rates for residues present in the human proteins are shown. Kernel density estimates of the distributions of dN/dS ratios per paralogous pair of proteins (**C--E**). *CLTA* and *CLTB* encode clathrin light chains A and B, respectively. *MMTR3* and *MMTR4* encode myotubularin lipid phosphatases. Mean dN/dS ratios averaged over all sites are shown as hatched marks.](elife-41517-fig2){#fig2}

Human population genetic analyses indicate purifying selection with ongoing diversification for *CLTCL1* {#s2-2}
--------------------------------------------------------------------------------------------------------

To follow up the indication that *CLTC* and *CLTCL1* are subject to different degrees of purifying selection, we investigated their variation in human populations. We analyzed 2504 genomes from the 1000 Genomes Project database, phase 3 (1000 [@bib5]) and identified alleles resulting from non-synonymous substitutions for *CLTC* and *CLTCL1.* This dataset included individuals from each of five human meta-populations: European (EUR, 503), East Asian (EAS, 504), Admixed American (AMR, 347), South Asian (SAS, 489) and African (AFR, 661). Individual populations with their abbreviations are listed in [Supplementary file 1a](#supp1){ref-type="supplementary-material"}. The reference sequences for chimpanzee (*Pan troglodytes*) and pseudo-references for two archaic humans, Altai Neanderthal and Denisovan, were also included to relate allelic variation to the ancestral state. A median-joining network for all the inferred *CLTC* human alleles showed a very common allele (sample frequency 0.997) with only five low-frequency variants generating a total of six alleles ([Figure 3A](#fig3){ref-type="fig"}). Each allele encodes a variant of a CHC (allotype), which includes one or more single nucleotide polymorphisms (SNPs).

![The *CLTCL1* gene encoding human CHC22 has two major variants, and is highly polymorphic relative to the human *CLTC* gene encoding CHC17, with a similar pattern in chimpanzees.\
Median joining network of human alleles for *CLTC* (**A**) and *CLTCL1* (**B**) are shown. Each circle represents a unique allele whose global frequency is proportional to its circle's size and the line length between circles is proportional to the number of non-synonymous changes between alleles. For *CLTC*, the least common alleles have a frequency ranging from 0.04% and 0.06% and the circles representing them were magnified by a factor of 10. For *CLTCL1*, only alleles with a frequency greater than 20% were plotted. The two major alleles show a combined frequency of 77% while the other alleles depicted in the figure have a frequency ranging from 0.44% to 5.67%. Segregation of the M1316V variation is depicted with a hashed line, with alleles carrying the M variant on the left-hand side, and alleles carrying the V variant on the right-hand side. The meta-populations in which the allele is found are indicated in color representing their percentage of the total frequency of the allele in humans. Meta-populations analyzed are African (AFR), American (AMR), East Asian (EAS), European (EUR), South Asian (SAS). (**C--D**) Median joining network of *CLTC* (**C**) and *CLTCL1* (**D**) alleles for chimpanzees (*Pan troglodytes*, four identified subspecies and one unidentified) and bonobos (*Pan paniscus*). The species and subspecies in which each variant is found are indicated in color representing their percentage of the of the total frequency of the variant in chimpanzees and bonobos.](elife-41517-fig3){#fig3}

In contrast to *CLTC*, we identified 46 non-synonymous SNPs in *CLTCL1*, present in 52 distinct haplotypes (referred to here as alleles, following the definition given above, [Supplementary file 2b-c](#supp2){ref-type="supplementary-material"}). A median-joining network for the most common *CLTCL1* alleles showed that they are widely distributed within the human meta-populations ([Figure 3B](#fig3){ref-type="fig"}). Each meta-population tends to have private, less frequent alleles. Nevertheless, all the meta-populations comprised two main allelic clades, together constituting a sample frequency of 77%. These two main alleles differ by a single methionine to valine substitution at position 1316 (M1316V) in the protein sequence (SNP ID rs1061325 with genomic location chr22:19184095 on hg19 assembly). The valine at position 1316 is predicted to have a functional effect on the protein since it was categorized as 'probably damaging' with a probability of 0.975 by PolyPhen ([@bib2]) and as 'damaging' by SIFT ([@bib48]). Sequences in chimpanzee and archaic humans have the M1316 allotype, suggesting that M1316 is likely to represent the ancestral state. To further investigate this, we inspected raw sequencing data from both Altai Neanderthal and Denisovan ([Supplementary file 1d](#supp1){ref-type="supplementary-material"}). We inferred the most likely genotype to be homozygous for the M1316 amino acid (minimum sequencing depths equal to 40 and 28, respectively). We then extracted sequencing data for an additional 13 archaic and ancient humans ([Supplementary file 1d](#supp1){ref-type="supplementary-material"}). We found that the V1316 amino acid is present in Pleistocene hunter-gatherers and Neolithic farmers but not in other Neanderthals or Holocene hunter-gatherers in this limited data set. The equivalent residue in human CHC17 (encoded by *CLTC*) is also methionine, suggesting that methionine at this position likely pre-dated the initial duplication generating *CLTCL1*. For the non-human species analyzed ([Figure 1](#fig1){ref-type="fig"}), all CHC-encoding genes present would produce clathrins with M1316, further indicating its ancient and conserved role in CHC structure or function.

To quantify the levels of nucleotide and allelic diversity for non-synonymous sites within human populations, several summary statistics of diversity were calculated. For populations within each meta-population, we separately calculated Watterson's and Nei's estimators of genetic diversity (TW and PI, respectively), Tajima's D (TD), Fu and Li's D\* (FLDs) and F\* (FLFs), the sum of squared allele frequencies including the most common allele (H1) and excluding it (H2), and the normalized ratio between H2 and H1 (H2H1) ([Supplementary file 2a](#supp2){ref-type="supplementary-material"}). To assess whether observed summary statistics are expected or not under neutral evolution in each population, we calculated the empirical null distribution from a set of 500 control genes with the same coding length as *CLTCL1* ([Supplementary file 2b](#supp2){ref-type="supplementary-material"}). High or low percentile rank values for *CLTCL1* in the empirical distribution indicate that the summary statistic for *CLTCL1* is unlikely to occur by mutation and neutral genetic drift alone. Summary statistics and populations were then clustered according to their empirical ranks and plotted on a heat map ([Figure 4](#fig4){ref-type="fig"}).

![Summary statistics for genetic diversity of *CLTCL1* indicate selection over neutral variation.\
For each human population (on the rows) we calculated several summary statistics to analyze diversity (on the columns, defined in Materials and methods) and reported their percentile rank against their corresponding empirical distribution based on 500 control genes. The resulting matrix was then sorted on both axes as a dendrogram (not reported) based on the pairwise distances between each pair of populations. The populations analyzed, with their abbreviations, are listed in [Supplementary file 1a](#supp1){ref-type="supplementary-material"}, and the inclusive meta-population is indicated in parentheses, defined as in the legend to [Figure 3](#fig3){ref-type="fig"}. As depicted in the color legend, red and yellow denote low and high percentile ranks, respectively. Percentiles lower than 0.10 or greater than 0.90 are given in the corresponding cell.](elife-41517-fig4){#fig4}

All populations tend to display high genetic diversity for *CLTCL1*, as summarized by PI and TW, and an unusually high frequency for the second most common allele, as summarized by H2 and H2H1. Such configuration is likely to occur under balancing selection ([@bib18]) or because of a soft sweep ([@bib59]). That *CLTCL1* was low ranking in all populations for H1, a statistic representing the frequency of the most common allele, also supported diversifying selection rather than hard sweeps. On the other hand, all populations display negative TD values with many populations exhibiting negative FLDs and FLFs values. These values are consistent with low diversity within common alleles and an excess of low-frequency variants. Finally, we calculated a measure of genetic differentiation (fixation index F~ST~) between pairs of canonical reference populations, namely Yoruba from Nigeria (YRI), North Americans with European ancestry (CEU), and Han Chinese from Beijing (CHB). We did not find any evidence that F~ST~ values for *CLTCL1* (YRI-CEU 0.15, YRI-CHB 0.077, CEU-CHB 0.065) are outliers in the empirical distribution of control genes.

Such inconsistent patterns could be partly explained by the fact that we considered only non-synonymous changes, and the limited number of SNPs considered per gene may create a larger variance in the empirical distributions, especially for allele-based statistics. We therefore further examined the high frequency of the second most common allele by investigating whole genomic variation, including silent SNPs. We observed a local increase of H2 statistics in *CLTCL1* for European populations, which already shows a large value based on non-synonymous changes ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). This analysis also indicates that any selection signatures are restricted to a local genomic region encompassing *CLTCL1*.

Another reason for the summary statistics not being strong outliers in the empirical distribution is the high recombination rate (sex-average rate of 2.5 cM/Mb) inferred for the genomic region encompassing *CLTCL1* ([@bib47]). We therefore performed coalescent simulations under neutrality of a putative 100kbp genomic region surrounding the SNP encoding the M1316V variation, taking into account the local recombination rate and a previously proposed demographic model for Africans (YRI), Europeans (CEU) and East Asians (CHB) ([@bib38]) with a mutation rate of 1.5 × 10^−8^ per base pair per generation. The observed values for TW and PI were significantly greater than expected under neutral evolution for all populations (p-values\<0.001), while TD was greater than expected for CHB only, although with a marginally non-significant statistical support (*p*-value 0.056). All these results are suggestive of a genetic diversity higher than expected under neutrality for a region encompassing M1316V, although possible complex evolutionary scenarios may limit the power of summary statistics to detect such selective events.

One plausible explanation of the high genetic diversity and frequency of the two major alleles of *CLTCL1* that occur in all modern human populations ([Figure 3B](#fig3){ref-type="fig"}, [Supplementary file 1b](#supp1){ref-type="supplementary-material"}) is balancing selection ([@bib18]). Such a distribution of allele frequency was confirmed using a different data set of more than 50 sampled human populations ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). In several populations, we also observed an apparent excess of heterozygosity at SNP rs1061325 ([Supplementary file 2c](#supp2){ref-type="supplementary-material"}), compatible with heterozygote advantage (overdominance) for the two encoded allotypes differing at residue 1316. Specifically, all European populations show a ratio of observed versus expected (assuming Hardy-Weinberg equilibrium) heterozygosity greater than 1, with the highest value of 1.24 (chi-squared test nominal *p*-value 0.047) for Iberic Spanish (IBS) ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Selective pressures that might be acting on *CLTCL1*, irrespective of population distribution, could be changes in human diet, a number of which have been inferred over the last 2.6 million years ([@bib41]). Perhaps the best known of these dietary transitions are the introduction of cooking \~450 KYA, the development of farming \~12,500 YA, and more recently industrialized food processing, which gradually and then dramatically increased carbohydrate availability and consumption by humans. As CHC22 clathrin, the gene product of *CLTCL1*, is required for formation of the intracellular pathway critical for an insulin response, its genetic history could potentially be influenced by these changes. To address the hypothesis that nutritional habits conferred selective pressure on *CLTCL1*, we compared the frequency of SNP rs1061325 (M1316V) in farming versus hunter-gatherer population samples from ancient and modern humans. Although the appearance of SNP rs1061325 predates the advent of farming ([Supplementary file 1d](#supp1){ref-type="supplementary-material"}), the observed frequencies of this allele, which encodes the CHC22-V1316 allotype, are consistent with a tendency for it to increase once farming became common practice for a population ([Figure 5](#fig5){ref-type="fig"}), although the small sample size for modern humans limits the power to reach statistical significance. The highest difference in allele frequency was observed between early farmers and hunter-gatherers from West Eurasia. However, as these two populations are highly diverged, it remains possible that this significant difference in allele frequency is due to genetic drift shaped by population history, rather than natural selection. To test this model, using the same dataset, we extracted 2500 control SNPs with a global minor allele frequency similar to rs1061325 (M1316V) (up to an error of 5%) and minimum global sequencing depth of 100X. We obtained statistical significance (*p*-value 0.036) when testing the difference in derived allele frequency in farmers compared to hunter-gatherers (+26.58%), while we found no statistical support (*p*-value 0.080) when testing the absolute difference in allele frequency between these two populations.

![Frequencies of the V1316 variant of CHC22 trend higher in populations of farmers compared to hunter-gatherers.\
Maximum a posteriori estimates and 95% highest posterior density credible intervals of the frequency of V1316 are compared for modern and ancient hunter-gatherer (HG) and farmer populations indigenous to three continents. Probability of the V allele being at a higher frequency in farmers, labeled as P(f \> hg), is also reported.](elife-41517-fig5){#fig5}

Genetic variation in non-human vertebrate species supports functional diversification of *CLTCL1* {#s2-3}
-------------------------------------------------------------------------------------------------

We analyzed allelic variation for *CLTC* and *CLTCL1* in the genomes of 79 individuals representing six species of great ape, two species each for chimpanzees, gorillas and orangutans (*Pan troglodytes*, *Pan paniscus*, *Gorilla beringei*, *Gorilla gorilla*, *Pongo abellii*, *Pongo pygmaeus*). After data filtering and haplotype phasing, we found no non-synonymous SNPs for *CLTC* and 64 putative non-synonymous SNPs for *CLTCL1* ([Supplementary file 3a](#supp3){ref-type="supplementary-material"}). In three species of great apes analyzed, one of the non-synonymous changes in *CLTCL1* leads to a premature stop-codon at amino position 41, with an overall frequency of 36%. However, sequences containing the stop-codon exhibited only a marginal increase of nucleotide diversity (+4.7% as measured by Watterson's index; [@bib91]) compared to the full-length sequences, suggesting that these are relatively new variants. Notably, for all the non-human primates analyzed, *CLTCL1* variants do not encode the V1316 allotype, which appears private to humans. However, in all three types of great ape we found a common but different substitution, threonine (T1316), at the same amino acid position.

To further investigate variation in non-human primates, we increased the sample size per species by analyzing *CLTC* and *CLTCL1* variation in 70 chimpanzee and bonobo genomes, including four subspecies of chimpanzee. While no variation was observed for *CLTC* ([Figure 3C](#fig3){ref-type="fig"}), a median-joining network for the inferred 8 *CLTCL1* alleles ([Supplementary file 3b](#supp3){ref-type="supplementary-material"}) showed a major allele common to different species and subspecies with less frequent alleles primarily restricted to individual ones ([Figure 3D](#fig3){ref-type="fig"}). In this chimpanzee data set, we observed considerable diversity, with a potential tendency towards multiple variants. However, amino acid 1316 was not covered in this data set, possibly due to poor data mapping quality associated with the high nucleotide diversity observed. In another data set of 20 individuals ([@bib85]), we found a frequency of 10% for the T1316 allotype in chimpanzees but not in bonobos.

We further investigated *CLTCL1* variation in polar bears (*Ursus maritimus*) and their closest related species, brown bears (*Ursus arctos*). These two species, which diverged 479--343 KYA ([@bib54]), have very different diets ([@bib54]; [@bib9]) and are phylogenetically closer to each other than chimpanzees and humans. Polar bears subsist on a high fat, low carbohydrate diet, whereas brown bears consume a more varied diet of carbohydrate, protein and fat. Analysis of 21 bear genomes (seven polar bears and 14 brown bears) ([@bib7]), revealed three positions (1267, 1389, and 1522) which are fixed in polar bears but are either polymorphic or have a different residue in brown bears ([Supplementary file 3c](#supp3){ref-type="supplementary-material"}). Genetic differentiation between polar and brown bears, as measured by F~ST~, is markedly higher for *CLTCL1* (0.56) than for *CLTC* (0.26) ([@bib54]). Furthermore, a phylogenetic tree of both bear species in our sample exhibits more diversification for *CLTCL1* compared to *CLTC* ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). This sample of bear populations may support the emergence of multiple *CLTCL1* variants within a species and a potential role for diet-related selection.

Modeling CHC22 variation based on *CLTCL1* polymorphism suggests an effect on clathrin lattice contacts {#s2-4}
-------------------------------------------------------------------------------------------------------

One expectation for selection of the human-specific *CLTCL1* allele encoding the CHC22-V1316 allotype is that this amino acid change might confer a functional change in the clathrin lattice. This was predicted by the PolyPhen and SIFT analyses, highlighting the change as potentially structure-altering. As many humans are heterozygous for the M1316 and V1316 allotypes (44% based on all individuals from 1000 Genomes project), there may potentially be special properties for mixed lattices formed from the two protein allotypes. To address the possibility that the M1316V polymorphism affects protein function, we used MODELLER ([@bib8]) to produce a homology model of the two CHC22 allotypes based on the crystal structure of CHC17 clathrin (PDB 1B89) ([@bib95]), taking advantage of the 85% protein sequence identity between human CHC17 and CHC22 ([Figure 6](#fig6){ref-type="fig"}). Modeling using UCSF Chimera ([@bib67]) showed that residue 1316 is found at a key interface between triskelion legs in assembled clathrin ([Figure 6A](#fig6){ref-type="fig"} and top of panel B). If M1316 is substituted by V1316, the smaller side chain creates a void that would be energetically unfavorable ([Figure 6](#fig6){ref-type="fig"}, bottom of panel B), such that the triskelion leg might twist slightly to close the void. In the clathrin lattice, the legs have a torque that rotates the assembly interface along the protein sequence ([@bib92]), so a further twist could slightly adjust the interface, altering assembly interactions. Changes in the assembly interface could affect integrity of the lattice and potentially influence kinetics of assembly and disassembly. Mixed lattices of the two CHC22 allotypes would therefore have different properties from CHC22 coats formed in homozygotes for the two major *CLTCL1* alleles. CHC22 is needed for the traffic of GLUT4 to its intracellular storage compartment, where GLUT4 awaits release to the plasma membrane in response to insulin. However, CHC22 also accumulates at the GLUT4 storage compartment (GSC) when it expands due to impaired GLUT4 release in cases of insulin-resistant type two diabetes (T2D) ([@bib88]). Thus, genetic variation of CHC22 could alter rates of retention and release of GLUT4 in both healthy and disease states.

![Modeling of the structural changes in clathrin caused by the methionine-valine dimorphism at residue 1316 predicts conformational alteration.\
Model of the CHC17 clathrin lattice (**A**) is reproduced with permission ([@bib30]) with the region comprising residue 1316 boxed. Panel B (top part) is the magnified boxed region in A with a CHC22-M1316 model (residues 1210 to 1516) docked into one of the four clathrin heavy chains (CHC-1) forming the edge of the lattice. The black arrow shows the location of the amino acid residue 1316 with the side chain highlighted in CHC-1. The density of the other three CHCs is indicated. Computational models of human CHC22 (residues 1210 to 1516) with either Met or Val at position 1316 (**B**, lower parts). The yellow circle encloses space opened by reducing the side chain size, which would require a shift in CHC torque to regain structurally favorable side chain contacts.](elife-41517-fig6){#fig6}

CHC22 variants display functional differences {#s2-5}
---------------------------------------------

To test whether the evolutionary change from M1316 to V1316 in CHC22 clathrin alters its properties, three aspects of CHC22 biochemistry and function were compared for the two allotypes. HeLa cells were transfected with constructs encoding each CHC22 variant or CHC17, tagged with green fluorescent protein (GFP). Atypically for their epithelial cell origin but not for transformed cells, HeLa cells express CHC22 clathrin (they are homozygous for the M1316 allotype) ([@bib1]; [@bib50]). We observed that the transfected fluorescently tagged CHC22 allotypes were both concentrated in the perinuclear region of the cell, similar to endogenous CHC22-M1316 detected by antibody, and did not overlap with endogenous CHC17 ([Figure 7A](#fig7){ref-type="fig"}). Conversely, transfected GFP-CHC17 did not overlap with endogenous CHC22, so expression of the transfected CHCs reflected their natural distribution ([@bib21]). Using these constructs, the dynamics of membrane association for the two allotypes of CHC22 and for CHC17 was assessed by Fluorescence Recovery After Photobleaching (FRAP). To assess clathrin turnover, as an indicator of clathrin coat stability, cells expressing fluorescent proteins were photobleached in the perinuclear area ([Figure 7B](#fig7){ref-type="fig"}) and their rate of fluorescence recovery was measured. Recovery of CHC17 fluorescence was the fastest, consistent with its more soluble properties compared to CHC22 ([@bib21]). CHC22-M1316 showed the slowest recovery and CHC22-V1316 was intermediate ([Figure 7C--E](#fig7){ref-type="fig"}), suggesting that it is more exchangeable in the CHC22 coat than the M1316 allotype.

![The CHC22-M1316 and CHC22-V1316 allotypes have different dynamics of membrane association, as measured by fluorescence recovery after photobleaching (FRAP).\
HeLa cells were transfected with CHC22-M1316-GFP (CHC22M) or CHC22-V1316-GFP (CHC22V) or CHC17-GFP and the expressed constructs were localized relative to endogenous CHC22 and CHC17, which were also compared to each other (**A**). Endogenous CHC22, CHC17 and the transfected proteins were visualized by immunofluorescence with anti-CHC22 rabbit polyclonal antibody (pAb, red), anti-CHC17 mouse monoclonal antibody (mAb, green) and anti-GFP chicken polyclonal antibody (green for CHC17-GFP or red for CHC22-GFP), respectively. Bars represent 3 μm (untransfected and CHC22M-GFP) and 5 μm (CHC22V-GFP and CHC17-GFP). Transfectants were photobleached in the circular region indicated (**B**) and recovery of fluorescence (FRAP) was visualized over time (bars, 10 μm) and quantified within the bleached regions (**C**). For the data in (**C**), area under the curves (**D**) and mobile fractions Mf (**E**) were calculated ([@bib52]). We performed a one-way analysis of variance (ANOVA) with Tukey's multiple comparison post-hoc test: \* p-value\<0.05, \*\* p-value\<0.01.\
10.7554/eLife.41517.016Figure 7---source data 1.FRAP experiment data set 1.\
10.7554/eLife.41517.017Figure 7---source data 2.FRAP experiment data set 2.\
10.7554/eLife.41517.018Figure 7---source data 3.FRAP experiment data set 3.](elife-41517-fig7){#fig7}

The impact of CHC22 variation on GLUT4 retention was then assessed. Because HeLa cells express CHC22, they can form a GSC, when transfected to express GLUT4. These cells sequester GLUT4 intracellularly, and then release it to the plasma membrane in response to insulin, behaving like muscle and adipocytes, though with more modest insulin response ([@bib16]; [@bib87]; [@bib40]). To detect GLUT4 release to the cell surface, we used a construct expressing GLUT4 tagged with mCherry and a hemagglutinin (HA) epitope embedded in an exofacial loop of the transporter (HA-GLUT4-mCherry). Appearance of surface GLUT4 in response to insulin was detected by fluorescence-activated cell sorting (FACS) using an antibody to the HA epitope ([Figure 8A](#fig8){ref-type="fig"}). Transfection of HeLa cells with siRNA depleting CHC22 ablates this insulin-responsive pathway ([@bib16]) ([Figure 8A](#fig8){ref-type="fig"}). We then assessed if siRNA inhibition of insulin-responsive GLUT4 release can be rescued by expression of CHC22-M1316-GFP or CHC22-V1316-GFP. These constructs, the same as characterized in [Figure 7A](#fig7){ref-type="fig"}, are siRNA-resistant, as well as being GFP-tagged. We observed that, when endogenous CHC22 was depleted, CHC22-M1316 was able to restore the insulin response but CHC22-V1316 was not, when the rescue constructs were expressed at the same levels in cells (measured by intensity of GFP fluorescence) ([Figure 8A](#fig8){ref-type="fig"}). CHC17 expression also did not rescue insulin-induced GLUT4 expression, as shown previously ([@bib88]). However, CHC22-V1316 is functional for trapping GLUT4 intracellularly because CHC22-transgenic mice that express CHC22-V1316 in muscle, using the natural human promoter, show excessive GLUT4 sequestration in muscle compared to wild-type mice without CHC22, leading to higher blood glucose in the transgenic animals ([@bib88]). To analyze GLUT4 sequestration in another way, cells depleted for CHC22 and then transfected with mCherry-GLUT4 plus either CHC22 allotype or CHC17 were each divided into three populations expressing equivalently low, medium and high levels of the transfected CHC-GFP. Then, the total GLUT4 content of the cells was measured by mCherry fluorescence. We observed higher levels of GLUT4 in CHC22-depleted cells expressing CHC22-M1316-GFP, compared to cells expressing either CHC22-V1316-GFP or CHC17-GFP at both medium and high levels of CHC expression ([Figure 8B](#fig8){ref-type="fig"}). This suggests that GLUT4 is sequestered more effectively from degradative membrane traffic pathways when trafficked by CHC22-M1316 than by CHC22-V1316, indicating that the M1316 variant is more efficient at targeting GLUT4 to the GSC. As indicated by their weak insulin response compared to muscle or fat cells, HeLa cells are only just able to form a functional GSC from which GLUT4 can be released. For these cells, the less effective CHC22-V1316 is inadequate to restore GSC formation when their endogenous CHC22-M1316 is depleted. Use of this HeLa model was necessitated by the lack of natural models for the CHC22-dependent GLUT4 pathway in myoblasts and adipocytes, as well as a lack of antibodies that detect surface GLUT4. Nonetheless, these experiments demonstrate a functional difference between CHC22-M1316 and CHC22-V1316 and suggest that CHC22-V1316 is less efficient at GLUT4 sequestration.

![Differences in intracellular GLUT4 sequestration and stability occur in cells expressing the CHC22-M1316 or CHC22-V1316 allotypes.\
HeLa cells were treated with siRNA to deplete endogenous CHC22 or with control siRNA, then transfected to co-express HA-GLUT4-mCherry along with CHC17-GFP (CHC17), CHC22-M1316-GFP (CHC22M) or CHC22-V1316-GFP (CHC22V) (**A** and **B**). Total levels of expressed GLUT4 and CHC were measured by FACS (mean fluorescence intensity (MFI) for mCherry or GFP, respectively). Surface levels of GLUT4 were measured with anti-HA antibody at basal conditions (-) or after 30 min of exposure to insulin (+) and surface/total GLUT4 is reported as a measure of GLUT4 translocation to the cell surface (**A**) in cells expressing equivalent total levels of CHC-GFP. The extent of GLUT4 translocation was assessed in each experimental group before and after insulin stimulation; Student t-test, \* p-value\<0.05. Transfected cells treated with siRNA to deplete endogenous CHC22, but not treated with insulin, were gated into thirds expressing equivalently low (L), medium (M) and high (H) levels of CHC-GFP for each type of CHC, then total levels of HA-GLUT4-mCherry in each population were plotted (**B**). We performed a one-way analysis of variance (ANOVA) with Tukey's multiple comparison post-hoc test: \* p-value\<0.05.\
10.7554/eLife.41517.020Figure 8---source data 1.GLUT4 translocation experiment.\
10.7554/eLife.41517.021Figure 8---source data 2.Total GLUT4-mCherry levels.](elife-41517-fig8){#fig8}

Discussion {#s3}
==========

We studied the phylogenetics and population genetics of CHC22 clathrin to understand the functional variation of this protein in relation to its evolutionary history. CHC22 clathrin is a key player in post-prandial blood glucose clearance in humans through its role in intracellular packaging of the GLUT4 glucose transporter in muscle and fat, the tissues in which CHC22 and GLUT4 are expressed ([@bib88]). The CHC22 pathway positions GLUT4 for cell surface release in response to insulin and consequent uptake of glucose into these tissues ([@bib15]). The *CLTCL1* gene encoding CHC22 resulted from gene duplication that we have now dated to 494--451 MYA, early in vertebrate evolution when jawed vertebrates emerged. We had previously shown that *CLTCL1* is a pseudogene in mice ([@bib90]). Expanding analysis to 56 jawed vertebrate genomes (\>5X coverage) we could not detect *CLTCL1* in nine of them. Six of these absences can be ascribed to two independent gene loss events in branches of the Rodentia and the Cetartidactylae. The three others may represent additional gene losses or incomplete genome annotation. All vertebrate and non-vertebrate eukaryotes considered here have retained the parent *CLTC* gene encoding CHC17 clathrin, which mediates endocytosis and other housekeeping membrane traffic pathways. The analysis described here establishes that *CLTC* is under strong purifying selection. Notable is our evidence for purifying selection on *CLTCL1* in the species in which it has been retained, supporting its functional importance in those species. Compared to *CLTC*, extensive allelic diversity was observed for *CLTCL1* in all species for which populations were analyzed, including humans, chimpanzees and bears. Variant alleles were species-specific in most cases. In all human populations, two allelic variants of *CLTCL1* are present in high frequency, differing only at one nucleotide, resulting in CHC22 protein with either methionine or valine at position 1316. The V1316 allotype appears specific to humans, but some non-human primates have a different variation at the position 1316. Analysis of ancient humans dated the appearance of the V1316 variant to 500--50 KYA and indicated that M1316, which is fixed in CHC17 clathrin, is the ancestral state. Analyses of human population genetic data provided support for the maintenance of high genetic diversity and two allotypes of CHC22. We hypothesize that selective pressure on CHC22 clathrin comes from its role in nutrient metabolism. Consistent with this hypothesis, we observed functional differences between the two CHC22 allotypes in their capacity to control GLUT4 membrane traffic, as predicted by structural modeling and differences in cellular dynamics of the two allotypes.

Retention of *CLTC* in all vertebrate species is consistent with the encoded CHC17 mediating cellular housekeeping clathrin functions shared by all eukaryotes. On the other hand, CHC22, encoded by the paralogous gene *CLTCL1*, operates in the specialized insulin-responsive GLUT4 pathway to make the pathway more efficient in those species that retained *CLTCL1*. Data presented here ([Figure 8](#fig8){ref-type="fig"}) and our recent mapping of a novel intracellular location for CHC22 function ([@bib16]) indicate that, in human cells, CHC22 clathrin promotes transport from the secretory pathway to the insulin-responsive GSC. This CHC22 pathway complements the endocytic pathway for GLUT4 targeting to the GSC, so species without CHC22 can rely primarily on endocytosis for GLUT4 trafficking to the GSC, while species with CHC22 use both pathways. Thus, we hypothesize that species with functional CHC22 clathrin are more efficient at intracellular GLUT4 sequestration, resulting in lower surface GLUT4 in the absence of insulin, and tighter regulation of GLUT4 release in response to insulin. The trade-off is that these species have an inherent increased tendency to insulin resistance as their GLUT4 is sequestered more effectively. The two main vertebrate branches that have lost CHC22 comprise the Muridae (mice and rats) who are incessant herbivores and the Cetartiodactyla (sheep, cattle, porpoise and pigs) which include the ruminants (sheep and cattle) whose muscle uptake of glucose is critical for muscle function, but is not a main pathway for glucose clearance ([@bib43]). These two groups of species require greater availability of GLUT4 on their cell surfaces, so that more efficient GLUT4 sequestration by CHC22 would not be favorable to their nutritional needs. The fact that CHC22 alters the balance of membrane traffic to the GSC means that species losing *CLTCL1* could evolve compensatory pathways more compatible with their diets. Thus, transgenic mice expressing CHC22 over-sequester GLUT4 in their muscle and develop hyperglycemia with aging ([@bib88]). The cave fish, which appears to lack *CLTCL1,* has independently evolved mutations in the insulin receptor, creating natural insulin resistance, such that the presence of CHC22 on top of this mechanism might be detrimental ([@bib74]). The loss of *CLTCL1* from cave fish is consistent with the insulin responsive GLUT4 pathway being a target for natural selection driven by diet, which might also explain *CLTCL1* variation or loss for additional vertebrate species during vertebrate evolution.

The allelic variation reported here for *CLTCL1* in human and bear populations further supports the hypothesis that *CLTCL1* has undergone continued selection during vertebrate evolution in relation to diet. While purifying selection appears to be operating on *CLTCL1* in those species that retain it, *CLTCL1* is far more variable than *CLTC* in these species. In humans, we find two major and functionally distinct alleles at remarkably similar frequencies in all populations studied. Statistical analysis comparing early farmer and hunter-gatherer populations shows an apparent increase of the V1316 variant, suggesting a correlation with regular consumption of digestible carbohydrate. Notably, the SNP distinguishing these alleles is human-specific and likely arose 550--50 KYA (i.e. post-Neanderthal split, pre-Neolithic). Other dramatic increases in digestible carbohydrate utilization have been inferred for humans in this timeframe; in particular the advent of cooking (which gelatinizes crystalized starch, making it much easier to digest), salivary amylase gene copy number increase (allowing increased starch digestion capacity) and accelerated brain size increase (which would increase demands for blood glucose) ([@bib41]). While the co-evolution of these cultural and genetic traits was originally proposed to have occurred some 800 KYA, recent studies indicate a time frame of 450--300 KYA years for cooking ([@bib77]), increased oral amylase activity ([@bib45]) and accelerated brain size increase ([@bib26]). The fact that the two major human *CLTCL1* alleles are functionally distinct is consistent with diversifying selection operating on *CLTCL1,* with a balancing selection possibly caused by heterozygote advantage. While population genetic signatures for balancing or overdominant selection were not entirely robust, some summary statistics were suggestive of an increased diversity that was unlikely to have occurred under neutrality. Other statistics, such as the ones based on allele frequencies, would not be expected to gain significance within the timeframe of the human-specific diversifying selection we detect. The allelic diversity of *CLTCL1* in other primate species could have the potential effect of diluting its function. Whilst chimpanzees are omnivores and gorillas herbivores, both rely for nutrition on extensive foraging for carbohydrate. Also notable is that polar bears, who have a very low carbohydrate diet compared to their brown bear relatives, have distinct CHC22 variants with unknown functionality, again consistent with *CLTCL1* undergoing selection driven by nutritional ecology.

Clathrins are self-assembling proteins and function as a latticed network in the protein coat that they form on transport vesicles. Our structural modeling predicts that the single amino acid difference between the two main human CHC22 allotypes could influence the strength of molecular interactions in the CHC22 clathrin lattice, as position 1316 occurs at a lattice assembly interface ([Figure 6](#fig6){ref-type="fig"}). When expressed in cells, both CHC22 variants gave the same overall intracellular distribution, but CHC22-V1316 shows faster turnover from membranes than CHC22-M1316 ([Figure 7](#fig7){ref-type="fig"}) and is less effective at GLUT4 sequestration ([Figure 8B](#fig8){ref-type="fig"}). These properties are consistent with the methionine to valine change attenuating GLUT4 retention. This interpretation is further supported by a GLUT4 translocation assay, which indicates that the V1316 variant is less effective in forming the insulin-responsive GSC than the ancestral M1316 form of CHC22 ([Figure 8A](#fig8){ref-type="fig"}). Thus, mixed lattices occurring in heterozygous individuals, potentially reflect balancing selection and overdominance, might reduce GLUT4 sequestration compared to M1316 homozygotes. This would have the effect of improving glucose clearance. It can be argued that human consumption of digestible carbohydrate on a regular basis ([@bib41]), requiring increased glucose clearance, might be a selective force driving this genetic adaptation. This view is consistent with the increased frequency of the V1316 variant in early farmers. It is also possible that some forms of polar bear CHC22 are super-active at GLUT4 sequestration, providing a route to maintain high blood glucose, as occurs through other mutations in the cave fish ([@bib74]).

Regulators of fundamental membrane traffic pathways have diversified through gene duplication in many species over the timespan of eukaryotic evolution. Retention and loss can, in some cases, be correlated with special requirements resulting from species differentiation, such as the extensive elaboration of genes in the secretory pathway of Tetrahymena ([@bib19]; [@bib11]). The evolutionary history of *CLTCL1*, following vertebrate-specific gene duplication, suggests that differentiation of nutritional habits has shaped selection for the presence and absence of *CLTCL1* in some vertebrate species, and its diversification in humans and potentially other species. Though its highest expression is in muscle and adipose tissue, transient expression of CHC22 during human brain development has also been documented ([@bib61]). This was noted in a study of a very rare null mutant of *CLTCL1* that caused loss of pain sensing in homozygotes and no symptoms for heterozygotes ([@bib61]). Attenuated CHC22 function of the V1316 variant might lead to a spectrum of pain sensing in humans but this is unlikely to be a strong selective force affecting reproductive success, whereas glucose homeostasis, as suggested by our analysis, is more likely. By exerting efficient control of blood glucose levels, the presence of CHC22 clathrin was likely beneficial in providing the nutrition required to develop the large human brain, as well as affecting reproduction by influencing glucose availability during pregnancy ([@bib41]). However, over the last 12,500 years in association with farming, or perhaps over the last 450,000 years in association with cooking, salivary amylase activity and starch digestion ([@bib41]; [@bib77]; [@bib45]), readily available carbohydrate has increased our need to clear glucose from the blood, such that selection continues to act on *CLTCL1* in humans. Our cell biology studies have also demonstrated that CHC22 increases GLUT4 retention. While we would not expect the major *CLTCL1* polymorphism to directly influence the development of T2D, CHC22 accumulates on the expanded GSC that forms in cases of insulin-resistant T2D ([@bib88]), so its variation could potentially exacerbate insulin resistance to different degrees. The genetic diversity that we report here may reflect evolution towards reversing a human tendency to insulin resistance and have relevance to coping with increased carbohydrate in modern diets.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\             Designation                                                Source or reference                                                              Identifiers                                                                            Additional\
  (species)\                                                                                                                                                                                                                                                   information
  or resource                                                                                                                                                                                                                                                  
  ------------------------- ---------------------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- -----------------------------------------------------------------
  Cell line (human)         HeLa                                                       ATCC                                                                             Cat. \#: CCL-2; RRID:[CVCL_0030](https://scicrunch.org/resolver/CVCL_0030)             

  Antibody                  Mouse monoclonal\                                          Frances Brodsky PMID: [2415533](https://www.ncbi.nlm.nih.gov/pubmed/2415533)                                                                                            IF (5 mg/mL)
                            anti-CHC17 (X22)                                                                                                                                                                                                                   

  Antibody                  Mouse monoclonal anti-CHC17 (TD.1)                         Frances Brodsky PMID: [1547490](https://www.ncbi.nlm.nih.gov/pubmed/1547490)                                                                                            WB (1.3 mg/mL)

  Antibody                  Rabbit polyclonal anti-CHC22 (SHL-KS)                      Frances Brodsky PMID: [29097553](https://www.ncbi.nlm.nih.gov/pubmed/29097553)                                                                                          WB (0.4 mg/mL)

  Antibody                  Mouse monoclonal anti-β-actin (AC-15)                      Sigma                                                                            Cat. \#: A1978; RRID:[AB_476692](https://scicrunch.org/resolver/AB_476692)             WB (1:2000)

  Antibody                  Purified anti-HA.11 (16B12)                                Covance                                                                          Cat. \#: MMS-101P; RRID:[AB_10064068](https://scicrunch.org/resolver/AB_10064068)      

  Antibody                  Rabbit polyclonal anti-CHC22                               Proteintech                                                                      Cat. \#: 22283--1-AP; RRID:[AB_11183764](https://scicrunch.org/resolver/AB_11183764)   

  Antibody                  Goat anti-rabbit IgG coupled to HRP                        ThermoFisher Scientific                                                          Cat. \#: 172--1019                                                                     WB (1:8000)

  Antibody                  Goat anti-mouse IgG coupled to HRP                         ThermoFisher Scientific                                                          Cat. \#: 170--6516                                                                     WB (1:8000)

  Antibody                  Anti-mouse IgG1 coupled to Brilliant Violet 421 (RMG1-1)   Biolegend                                                                        Cat. \#: 406616; RRID:[AB_2562234](https://scicrunch.org/resolver/AB_2562234)          FC (1:200)

  Recombinant DNA reagent   HA-GLUT4-mCherry                                           This paper                                                                                                                                                              Generated\
                                                                                                                                                                                                                                                               from HA-\
                                                                                                                                                                                                                                                               GLUT4-GFP\
                                                                                                                                                                                                                                                               (gift from Dr\
                                                                                                                                                                                                                                                               Tim\
                                                                                                                                                                                                                                                               McGraw,\
                                                                                                                                                                                                                                                               PMID: [11058093](https://www.ncbi.nlm.nih.gov/pubmed/11058093))

  Recombinant DNA reagent   CHC22V (pEGFP-C1-GFP-CHC22V)                               Frances Brodsky PMID: [20065094](https://www.ncbi.nlm.nih.gov/pubmed/20065094)                                                                                          

  Recombinant DNA reagent   CHC22M (pEGFP-C1-GFP-CHC22M)                               This paper                                                                                                                                                              Generated by Quick change mutagenesis from CHC22V

  Recombinant DNA reagent   CHC17 (pEGFP-C1-GFP-CHC17)                                 Frances Brodsky PMID: [29097553](https://www.ncbi.nlm.nih.gov/pubmed/29097553)                                                                                          

  Sequence-based reagent    AllStars Negative\                                         Qiagen                                                                           Cat. \#: SI03650318                                                                    
                            Control siRNA                                                                                                                                                                                                                      

  Commercial assay or kit   Quick change mutagenesis                                   New England Biolabs, USA                                                         Cat. \#: E0554S                                                                        

  Commercial assay or kit   BCA                                                        Pierce                                                                           Cat. \#: 23225                                                                         

  Commercial assay or kit   Western\                                                   GE Healthcare                                                                    Cat. \#: RPN2209                                                                       
                            Lightning Chemilumi-nescence Reagent                                                                                                                                                                                               

  Chemical\                 JetPrime\                                                  PolyPlus                                                                         Cat. \#: 114--07                                                                       
  compound, drug            transfection reagent                                                                                                                                                                                                               

  Chemical compound, drug   Insulin                                                    Sigma                                                                            Cat. \#: I9278                                                                         

  Chemical\                 Bovine serum albumin (BSA)                                 Sigma                                                                            Cat. \#: A7906                                                                         
  compound, drug                                                                                                                                                                                                                                               

  Software,\                FlowJo                                                     Treestar                                                                                                                                                                
  algorithm                                                                                                                                                                                                                                                    

  Software, algorithm       ImageJ                                                     NIH                                                                                                                                                                     

  Software, algorithm       Prism                                                      Graphpad                                                                                                                                                                

  Software, algorithm       R                                                          R Project                                                                                                                                                               Packages: pegas, Smisc, gplots

  Other                     CellView glass bottom culture dish                         Greiner Bio-one                                                                  Cat. \#: 627860                                                                        

  Other                     Nitrocellulose\                                            Biorad                                                                           Cat. \#: 1620112                                                                       
                            membrane                                                                                                                                                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Phylogenetics {#s4-1}
-------------

Vertebrate genomes as well as genomes of *Drosophila melanogaster*, *Caenorhabditis elegans*, *Ciona intestinalis* and *Ciona savignyi* were downloaded from Ensembl ([@bib94]), all accessed on 23/04/2016 except for pig (14/12/2017), marmoset and hagfish (both 09/08/2018), excluding vertebrate species sequenced below five-fold genome coverage, that is with less than five reads per site on average. In addition, we downloaded the genomes of the elephant shark ([@bib89]), whale shark ([@bib72]), marmot (The Alpine Marmot Genome, BioProject PRJEB8272 on NCBI) and porpoise ([@bib96]). All potential orthologs for the human isoforms of *CLTC/CLTCL1*, *MTMR4/MTMR3*, and *CLTA/CLTB*, in the above genomes were retrieved via BLAST ([@bib10]). An *e*-value threshold of 0.001 with additional constraints applied by default in InParanoid version 7 ([@bib65]) were used (at least 50% of the sequences are covered by the alignment, and at least 25% of the residues are aligned). The polar bear (*Ursus maritimus*) ([@bib54]), brown bear (*Ursus arctos*) ([@bib7]) and black bear (*Ursus americanus*) CHC17 and CHC22 protein sequences were manually added. For *CLTCL1* only the elephant and horse sequences (XP_023397213.1 and XP_023502410.1 respectively) were manually added.

The sequences corresponding to the longest transcripts were aligned with MAFFT ([@bib46]) and phylogenetic trees generated with PhyML ([@bib37]). The last two steps were repeated after manually removing outlier sequences lying on long branches (*CLTC/CLTCL1*: ENSTNIP00000007811.1, ENSTGUP00000014952.1, XP_023397213.1, XP_023502410.1; *CLTA/CLTB*: ENSPSIP00000012669.1) and, in the case of genomes not retrieved from Ensembl (therefore lacking the gene-to-transcript mapping), sequences most likely corresponding to alternative transcripts (XP_015350877.1, XP_007899998.1, XP_007899997.1, XP_007904368.1, XP_007904367.1, XP_020375861.1, XP_020375865.1, XP_020375862.1, XP_020392037.1, XP_020375864.1, XP_020375859.1). Trees were manually reconciled based on the Ensembl species tree extended by elephant shark, whale shark, brown bear, black bear, porpoise and marmot with TreeGraph ([@bib82]). Branch lengths were estimated based on the multiple sequence alignment (MSA) with PhyML fixing the manually reconciled topology, with options '-u' and '\--constraint_file'. With this approach no support values for splits are calculated. The resulting trees were used as input to generate a new phylogeny-aware MSAs with PRANK ([@bib55]). Branch lengths of the reconciled topologies were then re-estimated based on the MSA generated by PRANK.

To compute evolutionary rates, the sequences and subtrees corresponding to *CLTC* and *CLTCL1* clades after duplication (i.e. excluding non-vertebrates) were extracted and sequences from species without either *CLTC* or *CLTCL1* were removed. The same procedure was performed for *MTMR4/MTMR3* and *CLTA/CLTB*. A phylogeny-aware MSA was computed with PRANK on the remaining sequences, and the amino acid alignment was converted to a codon alignment with PAL2NAL ([@bib83]). Finally, dN/dS ratios (i.e. the ratio of the rate of nonsynonymous substitutions to the rate of synonymous substitutions) were inferred based on the codon alignments with PAML ([@bib93]) for the six proteins independently using the site model M7. Model M7 fits a Beta-distribution to the site rates by estimating the two Beta parameters shape and scale. Rates are estimated per site over the entire phylogeny, and therefore represent time averages. Phylogenetic trees of consensus amino acid sequences for bear samples only were computed using PhyML 3.1 ([@bib37]) with default values as implemented in Phylogeny.fr ([@bib23]).

Population genetics {#s4-2}
-------------------

Phased genotypes were obtained by querying Variant Call Format (VCF) files ([@bib20]) from the 1000 Genomes Project database Phase 3 (1000 [@bib5]) for all available 2504 samples. Only high-quality variants were retained using *vcflib* (<https://github.com/vcflib/vcflib>) with options 'VT = SNP and QUAL \> 1 and AC \>1 and DP \>5000'. Missing genotypes were assigned to homozygotes for the reference alleles. Finally, only sites with a recorded annotated function of being missense, nonsense, stop-loss or frame-shift for tested genes according to the UCSC Table Browser were retained ([@bib81]) (tables snp150 and snp150CodingDbSnp). For each retained position, the reference sequence for chimpanzee from the UCSC Table Browser ([@bib81]) (table snp150OrthoPt5Pa2Rm8) was initially used to infer the putative ancestral state. For ambiguous or multiallelic states in the chimpanzee sequence, the human reference base was used as an initial proxy for the ancestral state. The predicted functional impact of amino acid replacements was obtained by using Polyphen ([@bib2]) and SIFT ([@bib48]). Additional frequency information for a single mutation of interest in more than 50 human populations was retrieved from the HGDP CEPH Panel ([@bib17]) from <http://hgdp.uchicago.edu/cgi-bin/gbrowse/HGDP/>. Genotype data for farmer and hunter-gatherer individuals were collected from the Simons Genome Diversity Project Dataset ([@bib56]). Populations were merged based on their assigned geographical region with the following classification for hunter-gatherers: Africa (Biaka, Ju\|'hoan North, Khomani San, Mbuti), Central Asia and Siberia (Aluet, Chukchi, Eskimo Chaplin, Eskimo Naukan, Eskimo Sireniki, Even, Itelman, Tlingit, Tubalar, Ulchi, Atayal), East and South Asia (Atayal, Kusunda). Farmer and hunter-gatherer allele frequencies were compared following a previously described approach ([@bib71]). Briefly, we analytically computed the probability that the V allele is more frequent in farmers than in hunter gatherers while fully accounting for the uncertainty in the individual frequency estimates. V allele frequencies were inferred from allele counts of M and V in a Bayesian framework with a conjugate Beta uniform prior. We recorded maximum *a posteriori* estimates with 95% highest posterior density credible intervals computed with the *Smisc* R library, version 0.3.9. We collected further published ancient DNA data from Western Eurasia and classified into three genetic grouping: hunter-gatherer (HG), early farmer (EF) and steppe, using supervised ADMIXTURE ([@bib3]) as previously described ([@bib57]). These are genetic groups and not directly based on differences in material culture or subsistence, but importantly in the case of HG and EF, these genetic classifications correspond closely to hunter-gatherer and agricultural subsistence strategies ([@bib39]; [@bib80]; [@bib79]). We then restricted analysis to samples dated between 10,000 and 5,000 years before present that were classified as either HG or EF, leading to a dataset of 119 HG and 316 EF of which 85 and 188 respectively had coverage at rs1061325. Frequencies for South-East Asians and ancient Eurasians were down-sampled to ensure numerical stability. The HeLa genomic data were accessed through the NIH database of Genotypes and Phenotypes (dbGaP at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap>) through dbGaP accession number phs000640.

High-coverage VCF files for 79 individuals from six species of great apes were retrieved ([@bib68]). Data was filtered using *vcflib* on the combined data set with the options 'QUAL \> 32 and DP \>50 and DP \<7000 and FS \<27 and MQ \> 25 and AC \>1', similarly to the original manuscript describing this data set ([@bib68]). To retrieve nonsynonymous changes, only variants where the translated proteins for each allele differ were retained. We finally phased the data and assigned individual haplotypes using *shapeit* v2.r837 with the options '-burn 50 -prune 20 -main 100 -window 0.5 -effective-size 20000'. Additional 110 genomes of chimpanzees and bonobos were analyzed ([@bib85]; [@bib22]). Data filtering, functional annotation and haplotype phasing were performed as described above.

Full genome VCF files for two high-coverage archaic humans, namely one Altai Neanderthal ([@bib69]) and one Denisova were retrieved ([@bib60]). Low-quality sites were filtered out using *vcflib* with the options 'QUAL \> 1 and DP \>10'. A pseudo-reference sequence for each archaic human was constructed by replacing the heterozygous sites with the previously inferred human ancestral state. Sequencing data information for additional ancient human samples were obtained from previously published high-quality whole genome sequences ([@bib80]; [@bib14]; [@bib44]; [@bib51]; [@bib64]; [@bib70]; [@bib76]; [@bib31]). Genotype likelihoods were calculated using the standard GATK model ([@bib58]). Median-joining network plots were generated in R using *pegas* package ([@bib66]).

Several summary statistics were calculated on the inferred alleles to describe their levels of nucleotide diversity. Specifically, for each population separately, Watterson's estimator of population mutation parameter (TW) ([@bib91]), Nei's genetic diversity index (PI) ([@bib63]), Tajima's D (TD) ([@bib84]), Fu and Li's D\* (FLDs) and F\* (FLFs) ([@bib32]), the sum of squared allele frequencies including the most common allele (H1) and excluding it (H2) and their normalized ratio (H2H1) ([@bib35]; [@bib34]) were calculated. We also computed genetic differentiation (*F~ST~*) ([@bib73]) between pairs of canonical reference populations, namely Yoruban (YRI), Europeans (CEU), and Han Chinese (CHB).

To assess whether the observed summary statistics are expected under neutral evolution, genes with a coding length approximately equal (±5%) to the one observed for the tested gene, *CLTCL1*, were selected. For this analysis, the longest isoform for each gene, and its annotation was considered according to refGene table from the UCSC Genome Browser. We discarded genes on chromosome six and on sex chromosomes, as well as *CLTA*, *CLTB* and *CLTC*. This set was further reduced to the first 500 genes with the closest genomic length to *CLTCL1*. As summary statistics can be calculated only in case of genetic variability, genes showing no non-synonymous SNPs within each population were discarded. For each summary statistic, the empirical percentile rank for the value observed in *CLTCL1* compared to the whole distribution of control genes was calculated. Low or high values are suggestive of *CLTCL1* being an outlier in the empirical distribution. For plotting purposes, summary statistics and populations were clustered according to a dendrogram inferred from their respective distances based on the calculated matrix of empirical percentile ranks. That is, populations clustering together exhibit similar patterns of percentile ranks, and thus of summary statistics. The underlying dendrograms are not reported. The heatmap plot was generated using the function heatmap.2 in R with the package *gplots*. Cells with an empirical percentile rank lower than 0.10 or greater than 0.90 were filled with the exact rank value. We also obtained a null distribution of summary statistics by performing coalescent simulations using *msms* ([@bib29]) under a previously derived demographic model for human populations ([@bib38]).

Structure prediction by modeling {#s4-3}
--------------------------------

MODELLER v9.13 ([@bib8]) was used to model the structure of the proximal leg segment of CHC22, using the crystal structure of bovine CHC17 (PDB 1B89) ([@bib95]) as a template. The model of the M1316V mutant was derived in a similar way using a mutated sequence. Structure visualization and analysis of residue interactions at the mutation site M1316 were performed using UCSF Chimera ([@bib67]). The wild type and mutant homology models were positioned in the cryo-electron microscopy map of the bovine clathrin lattice (EMD: 5119) ([@bib30]) by structural superposition on the atomic model originally fitted in the map (PDB 1XI4).

Functional experiments {#s4-4}
----------------------

### Antibodies, plasmids and reagents {#s4-4-1}

Mouse monoclonal anti-CHC17 antibodies X22 ([@bib12]), TD.1 ([@bib62]) and affinity-purified rabbit polyclonal antibody specific for CHC22 and not CHC17 ([@bib88]) were produced in the Brodsky laboratory. Commercial sources of antibodies were as follows: mouse monoclonal anti-β-actin (clone AC-15, Sigma), mouse monoclonal anti-HA (clone 16B12, Covance), rabbit polyclonal anti-CHC22 (Proteintech). Secondary antibodies coupled to HRP were from ThermoFisher, the secondary antibody coupled to Brilliant Violet 421 was from BioLegend. The HA-GLUT4-mCherry was generated by replacing the GFP from the HA-GLUT4-GFP construct (gift from Dr Tim McGraw; [@bib49]) with mCherry using KpnI and EcoRI. The generation of the CHC22 variant expressing a valine at position 1316 (CHC22V) was previously described ([@bib28]). The CHC22 variant expressing a methionine at position 1316 (CHC22M) was generated from CHC22V by quick-change mutagenesis (New England Biotechnologies, USA) following manufacturer's instructions.

### Small RNA interference {#s4-4-2}

Targeting siRNA was produced to interact with DNA sequences AAGCAATGAGCTGTTTGAAGA for CHC17 ([@bib28]) (Qiagen), TCGGGCAAATGTGCCAAGCAA and AACTGGGAGGATCTAGTTAAA for CHC22 (1:1 mixture of siRNAs were used) ([@bib88]) (Dharmacon). Non-targeting control siRNA was the Allstars Negative Control siRNA (Qiagen).

### Cell culture {#s4-4-3}

HeLa cells were grown in Dulbecco's Modified Eagle Medium high glucose (Gibco) supplemented with 10% FBS (Gibco), 50 U/mL penicillin, 50 μg/mL streptomycin (Gibco), 10 mM Hepes (Gibco) and maintained at 37°C in a 5% CO~2~ atmosphere. HeLa cells were free of mycoplasma infection.

### siRNA and DNA transfection {#s4-4-4}

Cells were transfected for 72 hr with 20 nM of siRNA. Silencing was assessed by immunoblotting. Transient DNA transfections for rescue experiments were performed during the third day of silencing. For FACS experiments, cells (per well of 6-well plate, 70% confluent) were transiently transfected with 1 μg DNA for CHC22M-GFP and CHC22V-GFP, 1.5 μg DNA for CHC17-GFP and HA-GLUT4-mCherry. For FRAP experiments, cells (per glass bottom dish, 60% confluent) were transfected with 0.75 μg DNA for CHC22-GFP (M or V) or 1.5 μg DNA for CHC17-GFP. FACS and FRAP experiments were carried out 24 hr later. All transfections were performed using JetPrime transfection reagent (PolyPlus) following manufacturer's instructions.

### GLUT4 translocation assay using flow cytometry {#s4-4-5}

HeLa cells were grown in 6-well plates and transiently transfected with either HA-GLUT4-mCherry alone or in combination with GFP-tagged CHC22 (M or V) or CHC17-GFP the day before the experiment. The next day, cells were serum-starved (2 hr) before insulin stimulation (170 nM or vehicle (water) for 15 min, 37°C). Cells were then placed on ice and rapidly washed (2X, PBS, 4°C) and fixed (PFA 2%, 15 min). After fixation, cells were washed (2X, PBS, RT) then blocked for 1 hr (PBS 2% BSA, RT) before incubation with monoclonal anti-HA antibody (45 min, RT) to detect surface GLUT4. After incubation, cells were washed (3X, PBS, RT) and incubated with anti-mouse secondary Ig coupled to Brilliant Violet 421 (45 min, RT). Cells were then washed (5X, PBS, RT), gently lifted using a cell scraper (Corning), pelleted (800xg, 8 min) and re-suspended (PBS, 2% BSA, 4°C). Data was acquired with Diva acquisition software by LSRII flow cytometer (Becton Dickinson). Typically, 10,000 to 30,000 events were recorded and Mean Fluorescence Intensity (MFI) values for surface GLUT4 (Brilliant Violet 421) and total GLUT4 (mCherry) were recorded using 450/50 and 530/30 filters, respectively. The ratio of surface to total MFI was calculated to quantify the extent of GLUT4 translocation. MFI values for total GLUT4 (mCherry) were plotted for GLUT4 stability assays. Histograms and post-acquisition analysis were performed using FlowJo software (Treestar). Total GLUT4 and surface GLUT4 values are reported separately for cells expressing CHC22 variants with equalized GFP signals at the top third (high), middle third (medium) and bottom third (low) levels of expression.

### Fluorescence Recovery After Photobleaching {#s4-4-6}

The imaging of transiently transfected HeLa cells grown on Cellview glass bottom culture dishes (Greiner, Germany) was performed at 37°C in a 5% CO~2~ atmosphere, using low 488 nm laser power to minimize photobleaching using a 63x (1.4 NA) lens on a Leica SP8 confocal microscope. A 2.0 μm^2^ circular region of interest was positioned in the perinuclear region of the transfected cells, a region where both CHC22 and CHC17 naturally occupy. A 100% laser power (488 nm) coupled to 11 iterations was performed to achieve GFP photobleaching. Recovery of fluorescence was recorded from 4 to 10 independent cells per dish. The experiment was repeated at least three times.

### Immunoblotting {#s4-4-7}

HeLa cells protein extracts were quantified by BCA (Pierce), separated by SDS-PAGE (10% acrylamide), transferred to nitrocellulose membrane (0.2 μm, Biorad), labeled with primary antibodies (1--5 μg/mL), washed and labeled with species-specific horseradish peroxidase-conjugated secondary antibodies (ThermoFisher). Peroxidase activity was detected using Western Lightning Chemiluminescence Reagent (GE Healthcare). The molecular migration position of transferred proteins was compared to the PageRuler Prestain Protein Ladder 10 to 170 kDa (Thermo Fisher Scientific). Signals were detected using the Chemidoc XRS + imaging system (Biorad) and quantifications were performed using Image J software (NIH).

### Statistical analyses {#s4-4-8}

Graphs and statistical analyses were performed using Prism software (Graphpad). Detailed statistical information including statistical test used, number of independent experiments, *p*-values, definition of error bars is listed in individual figure legends. All experiments were performed at least three times.
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###### Human population genetics data.

(**a**) Human populations from the 1000 Genomes Project analyzed with their abbreviation. (**b**) Human alleles for the coding region of *CLTCL1* extracted from the 1000 Genomes project data set. For each unique allele (hap_ID on the first column), the count of occurrences in each meta-population (EUR, EAS, AMR, SAS, AFR defined as in the legend to [Figure 3](#fig3){ref-type="fig"}), archaic humans (Altai Neanderthal and Denisovan) and modern chimpanzees is reported. Columns numbered 1--46 indicate the nucleotide sequence at all retrieved SNPs present in each allele. Hap-1 is the most frequent allele encoding M1316 in CHC22 and Hap-2 is the most frequent allele encoding V1316 in CHC22. (**c**) Functional annotation for each coding polymorphism of *CLTCL1* reported in [Supplementary file 1b](#supp1){ref-type="supplementary-material"}. Columns represent chromosome, genomic position, SNP ID, reference allele, alternate allele and functional impact. (**d**) Archaic and ancient human M1316V genotypes retrieved. Genotype likelihoods and sources for each sample are reported.

10.7554/eLife.41517.023

###### Summary statistics and tests for neutrality.

(**a**) Summary statistics of genetic diversity for *CLTCL1* calculated for all analyzed human populations. Abbreviations for summary statistics (on the columns) are reported in Materials and methods while abbreviations for populations (POP, on the rows) are listed in [Supplementary file 1a](#supp1){ref-type="supplementary-material"}. (**b**) List of 500 control genes used to assess deviation from neutrality in the summary statistics of *CLTCL1*. (**c**) Expected and observed heterozygosity for M1316 and V1316 for all analyzed human populations. For each population (Pop., on rows, with abbreviations described in [Supplementary file 1a](#supp1){ref-type="supplementary-material"}), the frequency of observed homozygous (Obs.Homo1 and Obs.Homo2) and heterozygous genotypes (Obs.Hetero), the corresponding expected values under Hardy-Weinberg equilibrium (Exp.Homo1, Exp.Homo2, Exp.Hetero), the ratio (RatioHetero) between observed and expected heterozygosity, and *p*-values for deviation from Hardy-Weinberg equilibrium (chi-squared test) are reported.

10.7554/eLife.41517.024

###### Inferred allotypes for CHC22.

(**a**) Inferred CHC22 allotypes for great apes and human genome reference. For each unique allele (hap_ID on the first column), the frequency in each species or subspecies and the amino acid sequence at each numbered position in the encoded CHC22 allotype is reported. (**b**) Inferred CHC22 allotypes for chimpanzees and bonobos. For each unique allele (hap_ID on the first column), the frequency in each species or subspecies, and the amino acid sequence at each numbered position in the encoded CHC22 allotype is reported. (**c**) Differences in the amino acid sequences for CHC22 allotypes in bears. The first row depicts the species, while the second row is the originating country for each sample. All remaining rows are the numbered positions of the polymorphic sites in CHC22 encoded in brown bears and polar bears and indicate the amino acid is present in each sample's sequence. Amino acids for the reference sequences of black bears, pandas and humans are also reported at these polymorphic positions.

10.7554/eLife.41517.025

Data availability {#s7}
=================

All data generated or analysed during this study are included in the manuscript and supporting files.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The evolution of CHC22 clathrin influences its role in human glucose metabolism\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Patricia Wittkopp as the Senior Editor. The following individual involved in review of your submission has agreed to reveal his identity: Etienne Patin (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript entitled \"The evolution of CHC22 clathrin influences its role in human glucose metabolism\" studies the evolution in vertebrates of the *CLTCL1* gene, which encodes the clathrin CHC22 protein. Clathrin proteins assemble to form the lattice-like coat of vesicles that enable intracellular trafficking. CHC22-coated vesicles are known to regulate the sequestration of blood glucose via GLUT4 in muscle and fat, suggesting that *CLTCL1* is under changing selection pressures related to species nutritional intake. The study reports (i) a phylogenetic analysis of the *CLTCL1* gene and its paralog *CLTC*, revealing the presence or absence of the *CLTCL1* gene in published genomes of 62 species, (ii) an estimation of evolutionary rates of *CLTCL1* and its paralog *CLTC* in vertebrates, (iii) neutrality tests based on the intraspecies genetic diversity of the human species, and (iv) the functional characterization of the M1316V *CLTCL1* variant, a non-synonymous mutation that separates the two main haplotypes observed at *CLTCL1* in humans, and is differentiated between human populations with distinct modes of subsistence. The authors conclude that *CLTC* and *CLTCL1* have evolved under purifying selection in vertebrates, but functional genetic diversity in *CLTCL1* is larger than that of *CLTC* in humans and other great apes, suggesting diversifying or balancing selection. Although the work is of interest, and the analyses and interpretation generally straightforward, the authors provide only limited evidence in support of their main thesis that *CLTCL1* evolves under balancing selection in humans. This claim needs to bolstered in the revision, or alternative hypotheses considered and discussed.

Essential revisions:

1\) Balancing selection conclusion. The key pieces of populations genetics evidence offered are: (i) the *CLTCL1* gene presents a significant excess of singletons and significantly negative Tajima\'s D, which is indicative of positive or weak negative selection, (ii) the M1316V variant that separates the two most frequent haplotypes at the locus is differentiated across populations, while balancing selection is predicted to decrease FST (if balanced alleles have reached their equilibrium frequency in all populations), (iii) heterozygosity is both increased and decreased across human populations compared to HWE, and HWE is not tested. The authors propose no clear hypotheses that would explain overdominance of the two CHC22 forms. We suggest that the authors avoid claiming that the gene evolves under balancing selection, or provide stronger evidence for balancing selection. An intriguing observation made by the authors is the presence of seemingly shared *CLTCL1* polymorphisms between great ape species. The authors could confirm and explore this result further, as shared polymorphisms between species is a hallmark of balancing selection.

2\) Alternative hypotheses. High H2H1 statistics and correlations between allele frequencies and lifestyle are more compatible with a soft sweep scenario (including multiallelic positive selection/diversifying selection and positive selection on standing variation). However, evidence for positive selection could also be questioned, and suggests instead that the gene simply evolves under weak negative selection. Namely, (i) H2 values are not statistically significant, when considering a P-value significance threshold of 5%; (ii) the highest value that H2H1 can take depends on H12 (Garud and Rosenberg, 2015), suggesting that the ratio for *CLTCL1* should be compared to random genes with similar H12 values, or should be normalized; and (iii) differences in M1316V allele frequency between hunter-gatherer and farmer populations should be compared to an empirical distribution based on random SNPs with similar global frequency, to account for population differentiation.

3\) Bear species data. The analyses performed on bear species are very limited and not really informative. More importantly, no results are actually shown. Could the authors show, in a unique figure, networks for the two paralogous genes in both humans, chimps and bears? This will illustrate the systematically greater genetic diversity of *CLTCL1* relative to *CLTC*. Also, could the authors add the ancestral state in each network? This could help interpretation (under long-term balancing selection, the ancestral state should be found between the major haplotypes, contrarily to multiallelic positive selection or weak negative selection). Also could the authors describe the mutations that separate the most ancestral human haplotype from the second most frequent haplotype?

10.7554/eLife.41517.028

Author response

> Essential revisions:
>
> 1\) Balancing selection conclusion. The key pieces of populations genetics evidence offered are: (i) the CLTCL1 gene presents a significant excess of singletons and significantly negative Tajima\'s D, which is indicative of positive or weak negative selection, (ii) the M1316V variant that separates the two most frequent haplotypes at the locus is differentiated across populations, while balancing selection is predicted to decrease FST (if balanced alleles have reached their equilibrium frequency in all populations), (iii) heterozygosity is both increased and decreased across human populations compared to HWE, and HWE is not tested. The authors propose no clear hypotheses that would explain overdominance of the two CHC22 forms. We suggest that the authors avoid claiming that the gene evolves under balancing selection, or provide stronger evidence for balancing selection. An intriguing observation made by the authors is the presence of seemingly shared CLTCL1 polymorphisms between great ape species. The authors could confirm and explore this result further, as shared polymorphisms between species is a hallmark of balancing selection.

We agree with the reviewers that we did not find strong evidence for balancing selection, though some statistics are suggestive. We therefore toned down such claims and present balancing selection as a possible scenario to explain our findings. Likewise, we lighten the section on overdominance and move the corresponding figure into supplementary material. As requested, we now report statistical tests for deviation from HWE and found one European population to have a nominal significant p-value towards an excess of heterozygotes. However, we do not expect large and significant deviations from HWE unless selection is very strong. We now performed neutral simulations to test against neutrality for genetic diversity (as described below) to provide further indications of non-neutrality.

We have added a functional explanation for overdominance of the two forms in humans (mixed clathrin lattices would be formed with novel properties) and we have discussed how this might be favourable for handling increased glucose in the diet from the advent of cooking, in addition to farming.

The polymorphism observed in humans is not shared by great apes, though a different polymorphism is observed at the same coding position. This suggests that variation at this position may effectively change protein function, but that the frequent polymorphism observed only in humans may result from selection due to a human-specific behaviour, e.g. cooking or farming. We have clarified this where relevant.

> 2\) Alternative hypotheses. High H2H1 statistics and correlations between allele frequencies and lifestyle are more compatible with a soft sweep scenario (including multiallelic positive selection/diversifying selection and positive selection on standing variation). However, evidence for positive selection could also be questioned, and suggests instead that the gene simply evolves under weak negative selection. Namely, (i) H2 values are not statistically significant, when considering a P-value significance threshold of 5%; (ii) the highest value that H2H1 can take depends on H12 (Garud and Rosenberg, 2015), suggesting that the ratio for CLTCL1 should be compared to random genes with similar H12 values, or should be normalized; and (iii) differences in M1316V allele frequency between hunter-gatherer and farmer populations should be compared to an empirical distribution based on random SNPs with similar global frequency, to account for population differentiation.

Following the reviewers' suggestion, we have now calculated the normalized H2H1 statistics (as described in Garud and Rosenberg, 2015). These are now included in the new Figure 4. Please also note that we replaced the number of polymorphisms and singletons with two more commonly used metrics of diversity: Watterson's theta estimator (TW) and Nei's diversity (PI). Moreover, to be more conservative, we now restrict the control distribution to the 500 genes with the most similar genomic length to *CLTCL1* (in addition to the previous requirement of having a similar coding length).

Summary statistics can be highly influenced by the number of polymorphisms used. Furthermore, we noticed that *CLTCL1* lies in a highly recombining region (according to USCS Genome Browser tables, deCODE data). Therefore, we performed an additional analysis and simulated 1,000 genomic loci of 100kbp under neutral evolution to derive a second null distribution for nucleotide diversity for Africans, Europeans and East Asians. The genetic diversity, measured by Watterson's theta estimator (TW) and Nei's diversity (PI), for a 100kbp genomic region (therefore including silent SNPs too) surrounding M1316V is greater than expected by drift only, suggesting an excess of genetic diversity. This is now reported in the main text. These results are robust to the length of the genomic region considered (e.g. 50k, not reported in the main text). These findings suggest that the diversity we observed for *CLTCL1* is unlikely to be observed by genetic drift only, although Tajima's D does not appear to be statistically significant (although East Asians show higher Tajima's D than expected by neutrality with a marginally non-significant p-value).

As suggested by the reviewers, we compared the difference in allele frequency between ancient hunter-gatherers (HG) and early farmers in a set of control SNPs with a similar global minor allele frequency than M1316V. We performed this analysis only on the set of ancient HG and early farmers, as it was the only difference which appeared to be statistically significant based on the observed data. Specifically, we sampled non-synonymous polymorphisms with similar global minor allele frequency (+/- 5%) and with a minimum global sequencing depth of 100X. We randomly retrieved 2,500 control SNPs and tested how likely was to observe a difference in allele frequency between ancient HG and early farmers equal or greater than the value observed for M1316V (+0.2658). When considering the direction of the change in derived allele frequency, we found statistical significance (p=0.036), suggesting that population structure is unlikely to explain such increase in frequency for early farmers. On the other hand, we did not find statistical support (p=0.080) when we tested for the magnitude of the change (i.e. the module of the difference). These analyses have been added to the main text. Finally, these results are robust to the choice of the control distribution. In fact, if we restrict the control SNPs to be much closer to M1316V for the global minor allele frequency (+/- 2% with 1,250 random SNPs), we obtained p-values of 0.037 and 0.082 (not reported) when testing the sign and the module, respectively.

> 3\) Bear species data. The analyses performed on bear species are very limited and not really informative. More importantly, no results are actually shown. Could the authors show, in a unique figure, networks for the two paralogous genes in both humans, chimps and bears? This will illustrate the systematically greater genetic diversity of CLTCL1 relative to CLTC.

We are not able to provide haplotype networks for the bear species. For this data set we reconstructed a consensus amino-acid sequence for each individual and did not attempt to infer phased haplotypes due to low-coverage sequencing data, lack of reference data and limited sample size. Under these conditions, haplotypes would be phased with high uncertainty. Nevertheless, we include this data to address the reviewers' point that no data was provided. We now present Supplementary file 3C showing all private amino-acid substitutions in polar bears or brown bears for CHC22. We also generated a phylogenetic tree for *CLTC* and *CLTCL1* using this data set and provide it as Figure 3---figure supplement 1. The tree for *CLTCL1* exhibits a greater differentiation between polar and brown bears than *CLTC*.

Following the reviewers' suggestion, we now provide a unique figure with all 4 networks (*CLTC/CLTCL1* for humans and primates).

> Also, could the authors add the ancestral state in each network? This could help interpretation (under long-term balancing selection, the ancestral state should be found between the major haplotypes, contrarily to multiallelic positive selection or weak negative selection).

Putative human ancestral sequences (e.g. from archaic and chimp sequences) were inferred only for the non-synonymous sites which are polymorphic in humans. [Author response image 1](#respfig1){ref-type="fig"} shows a network for the most common alleles (circle I has M1316 while circle II has 1316V) in humans including the chimp reference sequence (circle XIV) and archaic humans (Altai Neandertal and Denisova, embedded in circles IV and VI, respectively). Therefore, the putative human ancestral state clusters with the M1316 group, as stated in the text. In the network, please note that sizing of major alleles was down-sized (as described in the text) for plotting purposes.

![](elife-41517-resp-fig1){#respfig1}

Furthermore, in [Author response image 2](#respfig2){ref-type="fig"} we show a network where we also included all fixed substitutions between the 8 most common alleles in humans (light blue) and the 3 most common ones in the primate data set (red, as proxy for the ancestral state). Here, the number of substitutions between each pair of alleles is shown. Again, results indicate that the putative ancestral form is closer to M1316 allele. Please note that due to the high polymorphic levels and recombination rates, networks on the full genomic region are not informative in this case. Please also note that sizes of major alleles were reduced for plotting purposes.

![](elife-41517-resp-fig2){#respfig2}

These plots (not included in the revised text) illustrate what we describe there for the reviewers and confirm that the putative ancestral state clusters within the M1316 allele. We do not observe the putative ancestral allele to be in the middle of the two main human alleles, possibly because there are only non-synonymous changes between clusters and/or due to the high genetic diversity in non-human primates.

> Also could the authors describe the mutations that separate the most ancestral human haplotype from the second most frequent haplotype?

There is only one mutation (M1316V) differing from the two most common alleles in the human data set. This is stated in the main text.

[^1]: These authors contributed equally to this work.
